A phase II trial of oral estramustine and oral etoposide in hormone refractory prostate cancer

Urology

Volumn 50, Issue 3, 1997, Pages 401-407

  Pienta, Kenneth J ^a   Redman, Bruce G ^a   Bandekar, Rajesh ^a   Strawderman, Myla ^a   Cease, Kemp ^a   Esper, Peggy S ^a   Naik, Harmesh ^a   Smith, David C ^a  

^a 5510 MSRB I ^*

Author keywords

[No Author keywords available]

Indexed keywords

ESTRAMUSTINE PHOSPHATE SODIUM; ETOPOSIDE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; EDEMA; FATIGUE; HORMONAL REGULATION; HUMAN; INFECTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; THROMBOCYTOPENIA; VEIN THROMBOSIS;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ESTRAMUSTINE; ETOPOSIDE; HUMANS; MALE; PROSTATIC NEOPLASMS; SURVIVAL RATE;

EID: 0030782928     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(97)00228-8     Document Type: Article

References (9)

1. Kantoff PW, Conaway M, Winer E, et al: Hydrocortisone (HC) with or without mitxantrone (M) in patients (pts) with hormone refractory prostate cancer (HRPC): preliminary results from a prospective randomized cancer and leukemia group B study (9182) comparing chemotherapy to best supportive care. Proc Am Soc Clin Oncol 15: 25, 1996.
2. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, Armitage GR, Wilson JJ, Venner PM, Coppin CM, and Murphy KC: Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14: 1756-1764, 1996.
3. Hudes GR, Greenberg R, Krigel RL, Fox S, Scher R, Litwin S, Watts P, Speicher L, Tew K, and Comis R: Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer. J Clin Oncol 10: 1754-1761, 1992.
4. Hudes GR, Nathan FE, Khater C, Greenberg R, Gomella L, Stern C, and McAleer C: Paclitaxel plus estramustine in metastatic hormone-refractory prostate cancer. Semin Oncol 22: 41-45, 1995.
5. Raghavan D, Cox K, Pearson BS, Coorey GJ, Rogers J, Watt WH, Coates AS, McNeil E, and Grygiel JJ: Oral cyclophosphamide for the management of hormone-refractory prostate cancer. Br J Urol 72(suppl 12): 625-628, 1993.
6. Sella A, Kilbourn R, Amato R, Bui C, Zukiwski AA, Ellerhorst J, and Logothetis C: Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer. J Clin Oncol 12: 683-688, 1994.
7. Kobayashi K, Vokes EE, Vogelzang NJ, Janisch L, Soliven B, and Ratain MJ: Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer. J Clin Oncol 13: 2196-2207, 1995.
8. Small EJ, Dawson NA, Kantoff PW, and Vogelzang NJ: Cancer and leukemia group B trials for advanced prostate cancer. Semin Oncol 23(suppl 14): 28-31, 1996.
9. Vogelzang NJ: One hundred thirteen men with hormone-refractory prostate cancer died today. J Clin Oncol 14: 1753-1755, 1996.